MIRA
INFORM REPORT
|
Report Date : |
13.10.2011 |
IDENTIFICATION DETAILS
|
Name : |
KOREA THUMB VET CO., LTD. |
|
|
|
|
Registered Office : |
740-1, Sinheung-dong, Iksan-si, Jeollabuk-do,
Korea 570-977 |
|
|
|
|
Country : |
South Korea |
|
|
|
|
Financials (as on) : |
31.12.2010 |
|
|
|
|
Date of Incorporation : |
04.10.2010 |
|
|
|
|
Com. Reg. No.: |
403-81-60128 |
|
|
|
|
Legal Form : |
Co., Ltd by Shares |
|
|
|
|
Line of Business : |
Manufacture of Animal Medicaments |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30, 2011
|
Country Name |
Previous Rating (30.06.2011) |
Current Rating (30.09.2011) |
|
South Korea |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Basic Information
|
Company
Name |
KOREA THUMB VET CO., LTD. (Korean Company Name : “한국썸벧(주)”) |
|
Registered Address |
740-1, Sinheung-dong, Iksan-si,
Jeollabuk-do, Korea |
|
Zip Code |
570-977 |
|
Tel |
+82-63-831-1275 |
|
Fax |
+82-63-831-1276 |
|
E-mail |
info@thumbvet.co.kr |
|
Website |
www.thumbvet.co.kr |
|
Trading Address |
740-1, Sinheung-dong, Iksan-si,
Jeollabuk-do, Korea |
|
Tel |
+82-63-831-1275 |
|
Fax |
+82-63-831-1276 |
|
Other Address-Bundang Office |
633, Sampyeong-dong,
Bundang-gu, Seongnam-si, Gyeonggi-do, Korea |
|
Tel |
+82-31-705-6464 |
|
Fax |
+82-31-705-4466 |
|
Type |
Export/Import |
|
Industry |
Manufacture of Animal Medicaments |
|
Main Business |
Antibiotics |
|
Established (mm/dd/yyyy) |
10/04/2010 |
Detailed Products
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Veterinary products(42121600) |
|
Sell |
Veterinary antibiotics(51102600) |
|
Sell |
Drugs used for respiratory tract
disorders(51161700) |
CEO’s
|
Name |
Lee Jung-Joo |
|
Address |
94-18, Sikgeum-ri,
Yangji-myeon, Cheoin-gu, Yongin-si, Gyeonggi-do, Korea |
|
Date of Birth |
12/26/1944 |
|
Title |
President & CEO |
|
Sex |
Male |
|
Nationality |
Korean |
Profiles
|
Capital (KRW) |
1,000,000,000 |
|||||||||
|
Employees |
33 |
|||||||||
|
Formation |
Co., Ltd by Shares |
|||||||||
|
Bank Details |
Hana Bank |
|||||||||
|
Corporate Registered No. |
214911-0033739 |
|||||||||
|
Business Registered No. |
403-81-60128 |
|||||||||
|
Permit & Licenses |
N/A |
|||||||||
|
Shareholder Position |
|
|||||||||
|
Company History |
10/04/2010 Incorporated as the present name |
|||||||||
|
|
|
Management
|
Job Description |
Title |
Name |
Sex |
Nationality |
Inauguration Date |
|
President & CEO |
Mr. |
Lee Jung-Joo |
Male |
Korean |
10/04/2010 |
|
Director |
Mr. |
Kum Hong |
Male |
Korean |
10/04/2010 |
|
Director |
Mr. |
Kim Jae-Kwan |
Male |
Korean |
10/04/2010 |
|
Auditor |
M/S. |
Park Hae-Sook |
Female |
Korean |
10/04/2010 |
Financials
|
Year / Unit : KRW |
Sales |
Assets |
Net Income |
|
6,753,098,500 |
42,784,223,504 |
8,232,537,214 |
Financial Description
|
Authorized Capital(KRW) |
4,000,000,000 |
|
Paid-Up Capital(KRW) |
1,000,000,000 |
|
Total Issues Shares |
200,000 |
Balance
Sheet
|
Unit : Korean Won |
10/04/2010~12/31/2010 |
As of 12/31/2009 |
As of 12/31/2008 |
|
Total Assets |
42,784,223,504 |
|
|
|
Current Assets |
9,860,377,096 |
|
|
|
-Quick Assets |
7,327,520,486 |
|
|
|
-Inventories |
2,532,856,610 |
|
|
|
Fixed Assets |
32,923,846,408 |
|
|
|
-Investment |
25,125,247,370 |
|
|
|
-Tangibles |
7,797,746,652 |
|
|
|
-Intangibles |
375,000 |
|
|
|
-Others |
477,386 |
|
|
|
Total Liabilities |
29,702,993,243 |
|
|
|
Current Liabilities |
29,065,848,493 |
|
|
|
Fixed Liabilities |
637,144,750 |
|
|
|
Capital Stock |
1,000,000,000 |
|
|
|
Capital Surplus |
3,848,693,047 |
|
|
|
Profit Surplus |
8,232,537,214 |
|
|
|
Capital Adjustment |
|
|
|
|
Total Equity |
13,081,230,261 |
|
|
|
Liab. & Shareholder’s Equity |
42,784,223,504 |
|
|
|
Current Liabilities |
29,065,848,493 |
|
|
|
Trade Payables |
1,185,087,485 |
|
|
|
Short-Term Borrowings |
9,500,000,000 |
|
|
|
Accrued Expenses |
64,547,251 |
|
|
|
Account Payables |
13,959,426,098 |
|
|
|
Advance Receipts |
6,371,025 |
|
|
|
Withholdings |
20,754,740 |
|
|
|
VAT Withhold |
191,661,254 |
|
|
|
Short-Term Borrowings-Foreign Currency |
1,569,479,350 |
|
|
|
Accrued Income Tax |
2,568,521,290 |
|
|
|
Fixed Liabilities |
637,144,750 |
|
|
|
Provision for Severance & Retirement |
17,144,750 |
|
|
|
Leasehold Deposit Received |
620,000,000 |
|
|
Income
Statement
|
Unit : Korean Won |
10/04/2010~12/31/2010 |
As of 12/31/2009 |
As of 12/31/2008 |
|
Sales |
6,753,098,500 |
|
|
|
Cost of Sold Goods |
5,262,201,013 |
|
|
|
Gross Profit |
1,490,897,487 |
|
|
|
Selling & Admin. Expenses |
371,595,494 |
|
|
|
Operating Income |
1,119,301,993 |
|
|
|
Non-Operating Income |
9,807,611,344 |
|
|
|
Non-Operating Expenses |
125,800,573 |
|
|
|
Income Before Taxes |
10,801,112,764 |
|
|
|
Income Taxes Expenses |
2,568,575,550 |
|
|
|
Net Income |
8,232,537,214 |
|
|
Cash
Flows
|
Unit : Korean Won |
10/04/2010~12/31/2010 |
As of 12/31/2009 |
As of 12/31/2008 |
|
Cash Flows from Operating |
13,998,293,761 |
|
|
|
-Net Income |
8,232,537,214 |
|
|
|
-Exp. without Cash Outflow |
109,336,679 |
|
|
|
-Revenue without Cash Inflows |
-9,706,663,152 |
|
|
|
-Changes in Asset/ & Liability |
15,363,083,020 |
|
|
|
Cash Flows from Investing |
-15,466,976,834 |
|
|
|
-Cash Inflow from Investing |
28,419,091 |
|
|
|
-Cash Outflows for Investing |
-15,495,395,925 |
|
|
|
Cash Flows from Financing |
1,200,876,141 |
|
|
|
-Cash Inflows from Financing |
1,500,000,000 |
|
|
|
-Cash Outflows from Financing |
-299,123,859 |
|
|
|
Increase/Decrease in Cash |
-267,806,932 |
|
|
|
Cash at the Beginning of Year |
2,140,284,200 |
|
|
|
Cash at the End of Year |
1,872,477,268 |
|
|
Products, Technologies, Services Description
|
Main Products & Services |
Antibiotics |
Trade Partners & Competitors
|
Suppliers |
GREEN BY-TECH CO., LTD.(214911-0011834) |
|
Customers |
SUNJIN CO., LTD.(134411-0046664) CHUNHAJEIL Co., Ltd.(214911-0034448) FARMSCO.(131111-0042950) HARIM Co., Ltd.(214911-0034430) |
|
Competitors |
DAESUNG MICROBIOLOGICAL LABS. CO.
LTD.(134111-0000880) BAYER KOREA LTD.(110111-0610596) BOEHRINGER INGELHEIM VETMEDICA KOREA
LTD.(110111-1218133) |
Related Parties
(Subsidiaries,
Joint-Venture & Affiliates)
|
Affiliates |
KOREA THUMBVET SALES CO., LTD.(131111-0037852) |
Sales by Region
(Activity & Markets)
Not Available.
Court Action
Not Available.
News Clipping
--
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.49.03 |
|
|
1 |
Rs.76.60 |
|
Euro |
1 |
Rs.66.80 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.